HRR as a Novel Biomarker in Sjögren's Syndrome

Status Completed

Clinical Trial Summary

Clinical Trial Description

Sjögren's syndrome (SS) is an autoimmune disorder characterized by chronic salivary and lacrimal gland dysfunction leading to dry mouth (xerostomia) and dry eye (xerophthalmia) sensation (1). Although dry mouth and dry eye are the main symptoms, the disease may influence many organs and systems. Diagnosis is made with ocular surface staining scores, anti-SS-A/SS-B auto-antibody positivity, and minor salivary gland biopsy (2). The Complete blood count (CBC) is a simple, inexpensive, accessible, and routinely used laboratory parameter that can be linked to oxidative stress, inflammation and microvascular flow resistance. Parameters include NLR and PLR values may be calculated by using CBC parameters (3). Neutrophil/lymphocyte ratio is used as an inflammatory marker in the diagnosis and prognosis of many cardiovascular diseases, malignancies, and infections (4-6). Peripheral inflammatory biomarkers of hematologic indices had been suggested by numerous studies to play a role during SS onset and progression. Sjögren's syndrome (SS) is a chronic autoimmune disease that primarily affects the exocrine glands, resulting in their functional impairment. In SS, lymphocytic infiltration of salivary and lacrimal glands, and deposition of several types of autoantibodies, mainly anti-SS-A (anti-Ro) and anti-SS-B (anti-La), lead to chronic inflammation, with xerostomia and keratoconjunctivitis sicca. In its primary form (pSS), SS does not involve additional connective tissue diseases. SS presents in association with other rheumatic autoimmune diseases, mainly rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis. Obviously, a prerequisite step in answering this critical question was to depict the change of inflammatory biomarkers of hematologic indices and disease activity progression in a detailed and comprehensive manner, and actually there were several studies aimed at answering this question. Along the hematologic indices field, most of the studies agreed that RDW was critical parameter in SS activity indication. As in most autoimmune diseases, environmental, hormonal and genetic factors are implicated in SS pathogenesis. have been shown to be a good serum marker in primary SS (pSS). All these indicated a potential linkage between systemic inflammation and the risk of SS. However, sparse evidence has been available on this association between the hematologic indices and SS. The aim of the present study, therefore, was to evaluate the association between systemic inflammation indices and SS. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05633524
Study type	Observational
Source	Tianjin Eye Hospital
Contact
Status	Completed
Phase
Start date	October 29, 2020
Completion date	November 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05946941` - A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome	Phase 3
Terminated	`NCT02843659` - Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome	Phase 2
Completed	`NCT04129164` - A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome	Phase 2
Completed	`NCT04798911` - SS-INQ Information Needs Questionnaire in Sjögren's Syndrome
Recruiting	`NCT05605665` - Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome	Phase 1/Phase 2
Completed	`NCT02833311` - e-Mobile Tablet for People With Chronic Conditions	N/A
Completed	`NCT04572841` - Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)	Phase 2
Completed	`NCT04111341` - A Clinical Trial to Evaluate the Safety and Efficacy of Traditional Chinese Medicine in Sjögren's Syndrome.	Phase 2
Recruiting	`NCT03060005` - Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?	N/A
Terminated	`NCT01316770` - Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects	Phase 2
Completed	`NCT02422407` - A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome	N/A
Completed	`NCT01160666` - Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome	Phase 2
Active, not recruiting	`NCT02849093` - Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.	N/A
Active, not recruiting	`NCT02112019` - Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome	N/A
Recruiting	`NCT03983408` - Impact of Korean Red Ginseng on Fatigue in Patients With Rheumatic Disease	N/A
Completed	`NCT00873496` - Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients	N/A
Completed	`NCT05680064` - The Effect of Chewing Gum, Exercises of the Tongue, Lip, Jaw on Salivation, Xerostomia, Dysphagia in Sjögren's Syndrome	N/A
Recruiting	`NCT02110446` - Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome	Phase 2
Recruiting	`NCT02855658` - Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome	Phase 2
Recruiting	`NCT03434106` - Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction	N/A